Scholarlink

Background <p>The Surpass Evolve (SE) is a second-generation flow diverter (FD) designed to improve procedural performance compared with earlier devices. This study aimed to evaluate the angiographic efficacy, safety, and clinical outcomes of SE in a single-center cohort with extended follow-up, comparing it to earlier-generation FDs.</p> Methods <p>We conducted a single-center comparative cohort study including 120 patients with unruptured intracranial aneurysms treated between 2014 and 2023. The prospective SE cohort (<i>n</i> = 67) was compared to a retrospective control cohort (<i>n </i>= 53; Surpass Streamline [SS] and Pipeline Embolization Device [PED]). Primary outcomes were complete aneurysm occlusion, major stroke, in-stent thrombosis, aneurysm enlargement, and unfavorable functional outcome. Secondary analyses included a composite safety endpoint and procedural parameters. Propensity score matching (PSM) was additionally performed to adjust for baseline imbalances, while multivariate Cox regression was used in the entire cohort to maximize statistical power.</p> Results <p>Complete occlusion was achieved in 79.1% of the SE cohort, with major stroke and in-stent thrombosis occurring in 1.5% each, and aneurysm enlargement in 3.0%. At last follow-up, 98.5% of SE patients had favorable functional outcomes (mRS 0–2). Compared with controls, the SE cohort had significantly fewer major strokes (1.5% vs. 13.2%, <i>p</i> = 0.029) and lower aneurysm enlargement (3.0% vs. 22.6%, <i>p</i> = 0.002). These findings remained consistent in the PSM-matched cohort, particularly regarding the prevention of aneurysm enlargement (<i>p</i> = 0.012). Procedural time was shorter (<i>p</i> = 0.001), and balloon angioplasty was less frequent (<i>p</i> = 0.023). SE use was independently associated with reduced aneurysm enlargement (adjusted OR, 0.14; <i>p</i> = 0.019). Cox analysis showed SS had lower occlusion probability (HR, 0.58; <i>p</i> = 0.047) than SE, while PED was similar.</p> Conclusions <p>In this single-center comparative cohort, SE demonstrated a favorable safety and efficacy profile, with lower rates of major stroke and aneurysm enlargement and improved procedural efficiency compared with earlier-generation devices.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Surpass evolve flow diverter in intracranial aneurysms: results from a single-center cohort with extended follow-up

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月7日

查看全文
  • Tae Keun Jee,
  • Hye Won Choi,
  • Je Young Yeon,
  • Keon Ha Kim,
  • Jong-Soo Kim,
  • Pyoung Jeon

摘要

Background

The Surpass Evolve (SE) is a second-generation flow diverter (FD) designed to improve procedural performance compared with earlier devices. This study aimed to evaluate the angiographic efficacy, safety, and clinical outcomes of SE in a single-center cohort with extended follow-up, comparing it to earlier-generation FDs.

Methods

We conducted a single-center comparative cohort study including 120 patients with unruptured intracranial aneurysms treated between 2014 and 2023. The prospective SE cohort (n = 67) was compared to a retrospective control cohort (n = 53; Surpass Streamline [SS] and Pipeline Embolization Device [PED]). Primary outcomes were complete aneurysm occlusion, major stroke, in-stent thrombosis, aneurysm enlargement, and unfavorable functional outcome. Secondary analyses included a composite safety endpoint and procedural parameters. Propensity score matching (PSM) was additionally performed to adjust for baseline imbalances, while multivariate Cox regression was used in the entire cohort to maximize statistical power.

Results

Complete occlusion was achieved in 79.1% of the SE cohort, with major stroke and in-stent thrombosis occurring in 1.5% each, and aneurysm enlargement in 3.0%. At last follow-up, 98.5% of SE patients had favorable functional outcomes (mRS 0–2). Compared with controls, the SE cohort had significantly fewer major strokes (1.5% vs. 13.2%, p = 0.029) and lower aneurysm enlargement (3.0% vs. 22.6%, p = 0.002). These findings remained consistent in the PSM-matched cohort, particularly regarding the prevention of aneurysm enlargement (p = 0.012). Procedural time was shorter (p = 0.001), and balloon angioplasty was less frequent (p = 0.023). SE use was independently associated with reduced aneurysm enlargement (adjusted OR, 0.14; p = 0.019). Cox analysis showed SS had lower occlusion probability (HR, 0.58; p = 0.047) than SE, while PED was similar.

Conclusions

In this single-center comparative cohort, SE demonstrated a favorable safety and efficacy profile, with lower rates of major stroke and aneurysm enlargement and improved procedural efficiency compared with earlier-generation devices.